

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/199458 A1

(51) International Patent Classification:

C12N 15/62 (2006.01) A61K 38/17 (2006.01)
C12N 15/26 (2006.01) A61K 38/20 (2006.01)
C07K 19/00 (2006.01) A61P 37/04 (2006.01)
C07K 14/55 (2006.01)

(21) International Application Number:

PCT/CN2024/084866

(22) International Filing Date:

29 March 2024 (29.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/084766

29 March 2023 (29.03.2023) CN

(71) Applicant (for CN only): **WUXI BIOLOGICS (SHANGHAI) CO., LTD.** [CN/CN]; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(71) Applicant (for all designated States except CN): **WUXI BIOLOGICS IRELAND LIMITED** [IE/IE]; Mullagharlin, Dundalk, Co Louth, A91 X56F (IE).

(72) Inventors: **WU, Lei**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **SUN, Mengmeng**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **WANG, Shuang**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **WU, Meng**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **XU, Jianqing**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **GU, Jijie**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(74) Agent: **CCPIT PATENT AND TRADEMARK LAW OFFICE**; 10/F, Ocean Plaza, 158 Fuxingmennei Street, Xicheng District, Beijing 100031 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IL-2 VARIANTS WITH IMPROVED STABILITY AND COMPOSITIONS THEREOF

(57) Abstract: Provided are IL-2 variants, polypeptide complexes comprising the IL-2 variants and compositions comprising the polypeptide complexes, the methods of producing the same and the uses thereof. The IL-2 variants and polypeptide complexes of the disclosure can be used as a potent agent for the treatment of cancers, autoimmune and inflammatory diseases.

WO 2024/199458 A1